Wells Fargo’s Enveric Biosciences ENVB Stock Holding History

Wells Fargo’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1	Hold	1	–	–	﹤0.01%	7250
2026 Q1	$2	Hold	1	–	–	﹤0.01%	7102
2025 Q4	$4	Buy	+1	New	+$7	﹤0.01%	6977
2025 Q3	–	Hold	0	–	–	–	7031
2025 Q2	–	Hold	0	–	–	–	7056
2025 Q1	–	Hold	0	–	–	–	6918
2024 Q4	–	Hold	0	–	–	–	6881
2024 Q3	–	Hold	0	–	–	–	6702
2024 Q2	–	Hold	0	–	–	–	6631
2024 Q1	–	Hold	0	–	–	–	6912
2023 Q4	–	Hold	0	–	–	–	6963
2023 Q3	–	Hold	0	–	–	–	6817
2023 Q2	–	Hold	0	–	–	–	6859
2023 Q1	–	Hold	0	–	–	–	7114
2022 Q4	–	Hold	0	–	–	–	6951
2022 Q3	–	Hold	0	–	–	–	6820
2022 Q2	–	Hold	0	–	–	–	6967
2022 Q1	–	Hold	0	–	–	–	7233
2021 Q4	–	Hold	0	–	–	–	6995
2021 Q3	–	Sell	-1	Closed	-$19.4K	–	6563
2021 Q2	$14K	Buy	+1	New	+$21.4K	﹤0.01%	6032
2021 Q1	–	Hold	0	–	–	–	6633
2020 Q4	–	Hold	0	–	–	–	6592
2020 Q3	–	Hold	0	–	–	–	6447
2020 Q2	–	Hold	0	–	–	–	6396
2020 Q1	–	Hold	0	–	–	–	6332
2018 Q1	–	Hold	0	–	-$31K	–	6415
2017 Q4	–	Hold	0	–	–	–	5680

Other funds holding ENVB

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wells Fargo's ENVB Position: Q2 2026 in Review

Wells Fargo held its Enveric Biosciences (ENVB) position steady in Q2 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #7250.

Wells Fargo first reported a position in ENVB in Q2 2021 and has held it in 4 quarters since. The position peaked at $14K in Q2 2021. 24 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

Wells Fargo held 1 share of Enveric Biosciences worth $1 as of Q2 2026.
Wells Fargo left its Enveric Biosciences share count unchanged in Q2 2026.
Enveric Biosciences made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #7250 holding.
Wells Fargo first reported a position in Enveric Biosciences in Q2 2021 and has held it in 4 quarters since.
Wells Fargo's Enveric Biosciences position peaked at $14K in Q2 2021.
24 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.